AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm aims to bring the tobacco spin-off’s developmental neuronal nicotinic receptor modulator TC-1734 to market for Alzheimer’s and other cognitive disorders.